1. Home
  2. Live Updates
  3. Tocilizumab

Live Breaking News & Updates on Tocilizumab

Stay informed with the latest breaking news from Tocilizumab on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Tocilizumab and stay connected to the pulse of your community

Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody

Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.

Anthony-perissinotti , Ryan-haumschild , Matthew-pianko , Practice-pearls , Immune-effector-cell , Associated-encephalopathyscoring , Pharmacy-times , Multiple-myeloma , Bispecific , Bispecific-antibodies , Adverse-event-profile

First Tocilizumab Biosimilar Approved in the United States

The FDA has approved Tofidence, the first tocilizumab biosimilar in the United States, which will be used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

China , Taiwan , United-states , Hong-kong , Macau , Ian-henshaw , Fresenius-kabi , Bio-thera-solution , Biosimilars , Tocilizumab , Fda-approval ,

Bispecifics in Multiple Myeloma: Adverse Event Management

Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.

Evolving-treatment-paradigm , Multiple-myeloma , Recent-updates , Adverse-event-management , Myeloma-cancer , Relapsed-refractory-multiple-myeloma , Multiply-relapsed , Later-line-treatment , Later-line-therapy , Adverse-events , Drug-adverse-event

Dr. Reddy's successfully completes Phase I study (IV route) of DRL_TC, a proposed biosimilar of tocilizumabp

Dr. Reddy's Laboratories Ltd. , a global pharmaceutical company, announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study.

United-states , Reddy-tocilizumab , Tocilizumab-roactemra , Tocilizumab-actemra , Jayanth-sridhar , Reddy-laboratories , Reddy-laboratories-ltd , Double-blind , Comparative-pharmacokinetic , Pharmacodynamic-study , Reference-tocilizumab , Intravenous-route

Dr. Reddy's successfully completes Phase 1 study of DRL_TC, a proposed biosimilar of tocilizumab

Dr. Reddy's Laboratories Ltd. announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase 1 study.

Jayanth-sridhar , Reddy-laboratories-ltd , Reddy-laboratories , Single-dose , Comparative-pharmacokinetic-study , Three-tocilizumab-products-administered , Subcutaneous-route , Normal-healthy-volunteer , Global-head , Laboratories-limited , Drreddyslaboratories , Ine089a01023

Clinical Challenges: Managing Adult-Onset Still's Disease

Immunomodulatory agents are shaping up for rare inflammatory disease

Houston , Texas , United-states , Tennessee , Kingsport , Nilanjana-bose , Christopherr-morris , Form-health-survey , Health-assessment-questionnaire , Arthritis-associates-in-kingsport , Morris , Lonestar-rheumatology

Roche gets USFDA priority review for Actemra to treat Covid-19

Basel: Roche today announced that the U.S. Food and Drug Administration (USFDA) has accepted the company's supplemental Biologics License Application (sBLA) and has granted Priority Review for...

Honduras , Australia , Philippines , Japan , United-states , Hong-kong , United-kingdom , Bolivia , Ghana , Ecuador , Chile , Peru

Non invasive ventilation with tocilizumab improves survival in hospitalized COVID-19 patients

Brazil: The use of simple oxygen only and noninvasive ventilation (NIV) was shown to be associated with a mortality benefit from tocilizumab in a Bayesian reanalysis of a previous meta-analysis of 15...

Brazil , Universidade-federal-do-rio-de-janeiro , Estado-do-rio , Rio-de-janeiro , Arthurm-albuquerque , School-of-medicine , Network-open-on , World-health-organization , Universidade-federal , Rates-among-hospitalized-patients-with , Treated-with-tocilizumab

Second JAK Inhibitor Shows Mortality Benefit in Severe COVID

U.K.'s RECOVERY trial finds baricitinib cut risk of death when added to usual care

Molly-walker , Martin-landray , Oxford-population-health , Baricitinib , Covid-19 , Covid , Tocilizumab , Remdesivir ,

Roche Drug: Arthritis Drug Added To World Health Organisation's List Of Covid Medicines

The World Health Organization said Friday that it had prequalified the arthritis treatment tocilizumab for use in patients hospitalised with severe Covid-19, in a bid to increase access to the pricey drug.

United-states , Switzerland , Swiss , European-union , World-health-organization , Covid-medicine-list , Tocilizumab , Tocilizumab-drug , World-health-organisation ,